Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04493671 · ClinicalTrials.gov registry record · Phase 1
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
A Phase 1 study, sponsored by Global Alliance for TB Drug Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 137
- Enrollment target
NCT04493671 is a Phase 1 study that has completed, run by Global Alliance for TB Drug Development. The registered enrollment target is 137 participants.
The verdict
NCT04493671, a Phase 1 study, has completed, sponsored by Global Alliance for TB Drug Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 137 participants
- Enrollment target
Study Summary
A Phase 1, Partially Blind, Placebo Controlled, Randomized, Combined Single Ascending Dose (SAD) with a Food Effect Cohort (Part 1), Multiple Ascending Dose (MAD) (Part 2), and Relative Bioavailability (rBA) (Part 3) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBAJ-876 in Healthy Adult Subjects
Interventions
- DRUG Placebo suspension
- DRUG TBAJ-876 suspension
- DRUG TBAJ-876 100 mg tablet
- DRUG TBAJ-876 25 mg tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2020-06-08 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04493671
The ClinicalTrials.gov registry entry for NCT04493671 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Global Alliance for TB Drug Development, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo suspension is the first listed.
NCT04493671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04493671 about?
NCT04493671 is a clinical study titled "Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults". A Phase 1, Partially Blind, Placebo Controlled, Randomized, Combined Single Ascending Dose (SAD) with a Food Effect Cohort (Part 1), Multiple Ascending Dose (MAD) (Part 2), and Relative Bioavailability (rBA) (Part 3) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBAJ-876 in Hea...
What is the current status of trial NCT04493671?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 137 participants. The study started on 2020-06-08. Estimated completion is 2022-11-15.
What interventions are being tested in trial NCT04493671?
The interventions under investigation include: Placebo suspension (DRUG), TBAJ-876 suspension (DRUG), TBAJ-876 100 mg tablet (DRUG), TBAJ-876 25 mg tablet (DRUG).
Who is sponsoring clinical trial NCT04493671?
This trial is sponsored by Global Alliance for TB Drug Development, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.